Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Galmed Pharma Adds China Arm to Phase IIb Trial of Liver Disease Drug

publication date: Jun 9, 2016
Galmed Pharma of Israel has expanded its Phase IIb clinical trial of aramchol, a liver disease treatment, to include a China arm. The announcement is significant because the Galmed trial is most likely one of the first Phase II multinational trials allowed in China. Before last August, when China revamped its regulations governing multinational trials, it was not possible for a company to add a China arm to a Phase II trial. Only Phase III multinational trials were allowed. Aramchol addresses a serious unmet need in China, which no doubt influenced the CFDA's decision. More details....

Stock Symbol: (NSDQ: GLMD)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital